Association between Low-Density Lipoprotein Cholesterol and Vascular Biomarkers in Primary Prevention

被引:2
|
作者
Kozakova, Michaela [1 ,2 ]
Morizzo, Carmela [3 ]
Jamagidze, Giuli [4 ]
Della Latta, Daniele [4 ,5 ]
Chiappino, Sara [4 ]
Chiappino, Dante [4 ]
Palombo, Carlo [3 ]
机构
[1] Univ Pisa, Dept Clin & Expt Med, I-56126 Pisa, Italy
[2] Esaote SpA, I-16152 Genoa, Italy
[3] Univ Pisa, Sch Med, Dept Surg Med & Mol Pathol & Crit Care Med, I-56126 Pisa, Italy
[4] Fdn Toscana G Monasterio, Imaging Dept, I-54100 Massa, Italy
[5] Fdn Toscana G Monasterio, Bioengn & Deep Hlth Units, I-54100 Massa, Italy
关键词
lipid-lowering treatment; primary prevention; coronary calcium; intima-media thickness; arterial stiffness; carotid artery; femoral artery; INTIMA-MEDIA THICKNESS; CORONARY-ARTERY CALCIFICATION; GRADE SYSTEMIC INFLAMMATION; STATIN THERAPY; CARDIOVASCULAR-DISEASE; EUROPEAN-SOCIETY; BLOOD-PRESSURE; RISK PROFILE; ATHEROSCLEROSIS; PROGRESSION;
D O I
10.3390/biomedicines11061753
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Several noninvasive vascular biomarkers have been proposed to improve risk stratification for atherothrombotic events. To identify biomarkers suitable for detecting intermediate-risk individuals who might benefit from lipid-lowering treatment in primary prevention, the present study tested the association of plasma LDL-cholesterol with coronary artery calcification (CAC) Agatston score, high carotid and femoral intima-media thickness (IMT), low carotid distensibility and high carotid-femoral pulse-wave velocity in 260 asymptomatic individuals at intermediate cardiovascular risk and without diabetes and lipid-lowering treatment. High or low vascular biomarkers were considered when their value was above the 95th or below the 5th percentile, respectively, of the distribution in the healthy or in the study population. LDL-cholesterol was independently associated with the CAC score = 0 (OR 0.67; 95%CI 0.48-0.92, p = 0.01), CAC score > 100 (1.59; 1.08-2.39, p = 0.01) and high common femoral artery (CFA) IMT (1.89; 1.19-3.06, p < 0.01), but not with other biomarkers. Our data confirm that in individuals at intermediate risk, lipid-lowering treatment can be avoided in the presence of a CAC score = 0, while it should be used with a CAC score > 100. CFA IMT could represent a useful biomarker for decisions regarding lipid-lowering treatment. However, sex- and age-specific reference values should be established in a large healthy population.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol
    Yeang, Calvin
    Karwatowska-Prokopczuk, Ewa
    Su, Fei
    Dinh, Brian
    Xia, Shuting
    Witztum, Joseph L.
    Tsimikas, Sotirios
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (11) : 1035 - 1046
  • [42] Fenofibrate lowers small low-density lipoprotein with no change in total low-density lipoprotein cholesterol
    Superko, HR
    Madan, S
    Tonnemacher, D
    Chronos, N
    Garrett, B
    Sheehan, D
    Raul, E
    Frohwein, S
    McGrath, K
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 316A - 316A
  • [43] ASSOCIATION BETWEEN SIZE OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND HIGH-DENSITY LIPOPROTEIN CHOLESTEROL PARTICLES AND CARDIOVASCULAR EVENTS IN TYPE 2 DIABETES SUBJECTS
    Lo Coco, G.
    Molina, J. Sanz
    Luciani, F.
    Semprini, C. M.
    Dalla Nora, E.
    Zuliani, G.
    Vigna, G. B.
    Passaro, A.
    ATHEROSCLEROSIS, 2020, 315 : E201 - E201
  • [44] New Strategies for Lowering Low-Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention
    Sean Paul Gaine
    Renato Quispe
    Jaideep Patel
    Erin D. Michos
    Current Cardiovascular Risk Reports, 2022, 16 : 69 - 78
  • [45] New Strategies for Lowering Low-Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention
    Gaine, Sean Paul
    Quispe, Renato
    Patel, Jaideep
    Michos, Erin D.
    CURRENT CARDIOVASCULAR RISK REPORTS, 2022, 16 (09) : 69 - 78
  • [46] Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol
    deGoma, Emil M.
    Leeper, Nicholas J.
    Heidenreich, Paul A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (01) : 49 - 55
  • [47] Low low-density lipoprotein cholesterol and cancer risk
    Strandberg, Timo E.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (01) : 91 - 92
  • [48] WEIGHT-REDUCTION RAISES HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND REDUCES LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PRIMARY HYPERCHOLESTEROLEMIA
    DAVIS, TA
    ANDERSON, EC
    VARHOL, A
    GOLDBERG, AP
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 1982, 35 (04): : 823 - 823
  • [49] WEIGHT-REDUCTION RAISES HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND REDUCES LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PRIMARY HYPERCHOLESTEROLEMIA
    DAVIS, TA
    ANDERSON, EC
    VARHOL, A
    GOLDBERG, AP
    CLINICAL RESEARCH, 1982, 30 (02): : A620 - A620
  • [50] Reliability of Calculated Low-Density Lipoprotein Cholesterol
    Meeusen, Jeffrey W.
    Snozek, Christine L.
    Baumann, Nikola A.
    Jaffe, Allan S.
    Saenger, Amy K.
    AMERICAN JOURNAL OF CARDIOLOGY, 2015, 116 (04): : 538 - 540